TrialBMC medicine2023

Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer's disease: a randomized phase 1 study.

Daizhuang Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.